A retrospective evaluation of vitamin K for hemoptysis in adult cystic fibrosis patients.
Elizabeth Marie GavioliKevin PaoMatthew HarringtonPublished in: Hospital practice (1995) (2021)
Evidence for the use of vitamin K therapy in the setting of CF-related hemoptysis remains unclear, and warrants further safety and efficacy evaluation. Further prospective studies are needed to determine the appropriateness of dosing and duration of vitamin K therapy, as well as determining its role in the setting of the varying levels of hemoptysis during a pulmonary CF exacerbation.
Keyphrases
- cystic fibrosis
- end stage renal disease
- pseudomonas aeruginosa
- ejection fraction
- chronic obstructive pulmonary disease
- newly diagnosed
- lung function
- chronic kidney disease
- pulmonary hypertension
- prognostic factors
- peritoneal dialysis
- intensive care unit
- patient reported outcomes
- young adults
- cell therapy
- acute respiratory distress syndrome
- drug induced